Monitoring of endothelial cell activation in experimental sepsis with a two-step cell culture model

Innate Immunity

Volumn 16, Issue 5, 2010, Pages 278-287

  Schildberger, Anita ^a   Rossmanith, Eva ^a   Weber, Viktoria ^a   Falkenhagen, Dieter ^a  

^a DANUBE UNIVERSITY KREMS   (Austria)

Author keywords

blood purification; cytokines; endothelial dysfunction; inflammation; lipopolysaccharide

Indexed keywords

CELL ADHESION MOLECULE; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL CULTURE; CELL ACTIVATION; CELL CULTURE MONITORING; CELL STIMULATION; CELL STRAIN THP 1; CELL SURFACE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; EXPERIMENTAL INFECTION; EXPERIMENTAL MODEL; HEMODIALYSIS; HUMAN; HUMAN CELL; MODULATION; MOUSE; NONHUMAN; PLASMA; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; SEPSIS; SUPERNATANT; UMBILICAL VEIN;

CELL CULTURE TECHNIQUES; CELL LINE; CYTOKINES; ENDOTHELIAL CELLS; HUMANS; LIPOPOLYSACCHARIDES; MONOCYTES; NF-KAPPA B; PSEUDOMONAS AERUGINOSA; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA; UMBILICAL VEINS;

PSEUDOMONAS AERUGINOSA;

EID: 78649644431     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425909341885     Document Type: Article

References (28)

1. Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Med 2003 ; 29: 530-538.
2. Angus DC, Linde-Zwirble WD, Lidicker J., Clermont G., Carcillo J., Pinsky MR Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001 ; 29: 1303-1310.
3. Martin GS, Mannino DM, Eaton S., Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003 ; 348: 1546-1554.
4. O'Brien JM, Ali NA, Aberegg SK, Abraham E. Sepsis. Am J Med 2007 ; 120: 1012-1022.
5. Medhzitov R., Janeway C. Innate immune recognition: mechanisms and pathways. Immunol Rev 2000 ; 173: 89-97.
6. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007 ; 449: 819-826.
7. Cohen J. The immunopathogenesis of sepsis. Nature 2002 ; 420: 885-891.
8. Annane D., Bellisant E., Cavaillon JM Septic shock. Lancet 2005 ; 365: 63-78.
9. Markiewski MM, Nilsson B., Ekdahl KN, Mollnes TE, Lambris JD Complement and coagulation: strangers or partners in crime? Trends Immunol 2007 ; 28: 184-192.
10. Ward P. The dark side of C5a in sepsis. Nat Rev Immunol 2004 ; 4: 133-142.
11. Lehr HA, Bittinger F., Kirkpatrick CJ Microcirculatory dysfunction in sepsis: a pathogenic basis for therapy? J Pathol 2000 ; 190: 373-386.
12. Aird WC The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003 ; 101: 3765-3777.
13. Ploder M., Pelinka L., Schmuckenschlager C. et al. Lipopolysaccharide- induced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. Shock 2006 ; 25: 129-134.
14. Hotchkiss RS, Nicholson DW Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006 ; 6: 813-822.
15. Marshall JC Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov 2003 ; 2: 391-405.
16. Riedemann NC, Guo RF, Ward PA Novel strategies for the treatment of sepsis. Nat Med 2003 ; 5: 517-524.
17. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant activated protein C for severe sepsis. N Engl J Med 2001 ; 344: 699-709.
18. Bellomo R., Honoré P., Matson J., Ronco C., Winchester J. Extracorporeal blood treatment methods in SIRS/sepsis. Int J Artif Organs 2005 ; 28: 450-458.
19. Jaber BL, Pereira PJG. Extracorporeal adsorbent-based strategies in sepsis. Am J Kidney Dis 1997 ; 30: S44-S56.
20. Falkenhagen D., Schima H., Loth F. Arrangement for removing substances from liquids, in particular blood. Patent WO9504559; Japanese Patent #50 1083 (1997). US Patent #5, 855, 782 ( 1999 ).
21. Ronco C. The immunomodulatory effect of extracorporeal therapies in sepsis: a reconciliation of three theories. Int J Artif Organs 2007 ; 30: 855-857.
22. Schefold JC, von Haehling S., Corsepius M. et al. A novel selective extracorporeal intervention in sepsis: immunoadsorption of endotoxin, interleukin 6, and complement-activating product C5a. Shock 2007 ; 28: 418-425.
23. Rittirsch D., Flierl MA, Ward PA Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008 ; 8: 776-787.
24. Magder S., Neculcea J., Neculcea V., Sladek R. Lipopolysaccharide and TNF-α produce very similar changes in gene expression in human endothelial cells. J Vasc Res 2006 ; 43: 447-461.
25. López-Bojórquez LN, Arechavaleta-Velasco F., Vadillo-Ortega F., Móntes-Sánchez D., Ventura-Gallegos JL, Zentella-Dehesa A. NF-κB translocation and endothelial cell activation is potentiated by macrophage-released signals co-secreted with TNF-α and IL-1β. Inflamm Res 2004 ; 53: 567-575.
26. Zhao B., Bowden RA, Stavchansky SA, Bowman PD Human endothelial cell response to Gram-negative lipopolysaccharide assessed with cDNA microarrays. Am J Physiol 2001 ; 281: C1587-C1595.
27. Sharif O., Boshakov VN, Raines S., Newham P., Perkins ND Transcriptional profiling of the LPS induced NF-κB response in macrophages. BMC Immunol 2007 ; 8: 1.
28. Hein OV, Misterek K., Tessmann J-P., van Dossow V., Krimphove M., Spies C. Time course of endothelial damage in septic shock: prediction of outcome. Crit Care 2005 ; 9: R323-R330.